Strainprint Technologies Ltd, the leader in cannabis data and analytics is pleased to welcome Calyx Peak Companies (Calyx Peak) to their growing list of customers across North America.

Calyx Peak employs a diverse team of medical, business, construction and cannabis industry experts across the U.S. who invest, operate and manage assets throughout the legal cannabis market. The company manages multiple cannabis-centric operations in California, Ohio, Nevada and Massachusetts, overseeing twenty seven permits and 300,000-square feet of cultivation greenhouse facilities and production facilities.

“Aligning with Strainprint gives us access to the best-in-class cannabis data available to ensure we produce optimal products for our customers,” said Edward Schmults, CEO of Calyx Peak.

The fast-growing company will access the Strainprint Analytics web platform, the most sophisticated cannabis analytics platform available, to improve product development, monitor customer performance and provide a better treatment experience.  Strainprint Analytics is built on top of the largest and most granular scientific data set of its kind in the world, with more than 1.3 million anonymized, patient reported medical cannabis outcomes and more than 65 million data points on strain efficacy.

“Our objective is to use their crowdsourced efficacy data to further understand the benefits of the strains we’re growing,” continued Schmults. “We have the highest standard for our products, so by looking at the unique chemovar profiles of our strains and comparing to Strainprint’s patient-led data, we can better recognize what our strains can deliver as far as relief, potentially treating numerous symptoms such as sleep deprivation, anxiety, chronic pain and much more.”

“We’re happy to extend our real-time technology platform and provide our cannabis product suite to organizations who share mutual passions and goals,” said Strainprint CEO, Andrew Muroff. “We have a similar philosophy to Calyx Peak and that is to craft a modern cannabis experience through the scientific understanding of cannabis and its legitimacy as a therapy.”

SOURCE Strainprint Technologies Ltd.